Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. (PPCB) generates news that spans oncology research, clinical development, corporate finance, and its emerging digital asset strategy. As a biopharmaceutical company focused on proenzyme-based therapies for recurrent and metastatic cancer, Propanc’s updates often center on its lead candidate PRP, a combination of pancreatic proenzymes designed to target cancer stem cells, modulate epithelial-to-mesenchymal transition (EMT), and influence the tumor microenvironment.
News coverage commonly highlights scientific and clinical milestones, including preclinical findings in pancreatic ductal adenocarcinoma (PDAC) models, publications with academic collaborators, and plans for a Phase 1b First-In-Human study in patients with advanced solid tumors. Press releases describe how PRP may affect cancer-associated fibroblasts, tumor angiogenesis, cell migration, and chemosensitivity, as well as its potential relevance to chronic conditions such as fibrosis.
Investors following PPCB can also expect corporate and financial updates, such as details of the company’s Nasdaq listing, public offerings, and structured financing agreements. Recent announcements have described a private placement facility of up to $100 million in Series C Preferred Stock and warrants, intended to support both the R&D pipeline and a strategy to build a digital asset treasury through potential acquisitions of digital asset treasury companies.
Additional news items address intellectual property developments, including new patent filings for methods of treating resistant cancers and fibrosis, and extensions of Propanc’s POP1 joint research program with the Universities of Jaén and Granada. Together, these releases provide insight into how the company is advancing its proenzyme technology, expanding its patent estate, and structuring its balance sheet.
For readers tracking PPCB, the news stream offers a consolidated view of scientific progress, trial planning, financing transactions, and strategic initiatives that shape Propanc Biopharma’s evolution as a development-stage oncology company.
Propanc Biopharma (Nasdaq: PPCB) on Jan 27, 2026 filed a fourth provisional patent application in two months with IP Australia covering improved formulations of pancreatic proenzymes trypsinogen and chymotrypsinogen, the active components of its lead asset PRP. The filing targets stability, storage, freeze/thaw resilience and global transport challenges for proenzyme pharmaceutical compositions used in cancer and chronic diseases.
The company said these provisional filings, as they move to national phase entry, are expected to expand its patent estate from ~90 to >200 patents across compositions, formulations, treatment methods and indications, and support preparations for a Phase 1b first-in-human study in advanced cancer patients.
Propanc Biopharma (NASDAQ:PPCB) filed a new provisional patent application with IP Australia on January 20, 2026 for methods to produce fully synthetic recombinant trypsinogen and chymotrypsinogen (Rec-PRP).
The filing describes an optimized yeast-based expression system to manufacture a world-first fully synthetic version of PRP intended as a long-term therapy to treat and prevent metastatic cancer from solid tumors. Management says Rec-PRP could enable long shelf life without refrigeration, scalable lot-consistent supply without animal sourcing, and improved global distribution. The release cites a projected global metastatic cancer market of $111 billion by 2027 and frames the provisional as the third filing in two months to expand the company IP portfolio ahead of national phase filings worldwide.
Propanc Biopharma (Nasdaq: PPCB) described preclinical and market context for its pancreatic proenzyme candidate PRP and outlined next steps toward human studies in 2026. Key facts: PRP is a 1:6 mixture of trypsinogen and chymotrypsinogen; preclinical models showed tumor growth inhibition >85% at some doses and reduced EMT, angiogenesis, and fibrosis; FDA granted Orphan Drug Designation (2017). The company is pre-revenue, raised ~$4M in a recent IPO, and cited a potential $100M private placement facility to fund development. Phase I/II trials are planned for 2026.
Propanc Biopharma (Nasdaq: PPCB) provided a shareholder update on Jan 13, 2026 outlining 2025 progress and 2026 plans. The company said it will advance lead candidate PRP into a Phase 1b First‑In‑Human study in ~30–40 patients with advanced solid tumors at Peter MacCallum Cancer Centre in 2026. Propanc reported it raised $4 million after up‑listing to Nasdaq to fund clinical preparations, has invested over $30 million since inception, and holds an IP portfolio of 90+ issued patents. The update also described preclinical work on a synthetic backup Rec‑PRP and research into PRP for fibrosis, with key clinical manufacturing and PK method milestones expected by Q3 2026.
Propanc Biopharma (Nasdaq: PPCB) and partners published peer‑reviewed results in Scientific Reports (Dec 22, 2025) on the impact of pancreatic proenzymes (PRP) on pancreatic ductal adenocarcinoma (PDAC) fibroblasts.
The study reports that PRP, composed of bovine trypsinogen and chymotrypsinogen, exerts multifaceted effects on cancer‑associated fibroblasts (CAFs) and tumor cells and is described as a potential disruptor of the tumor microenvironment (TME). The company plans a Phase 1b clinical study in advanced solid‑tumor patients in Q3 2026 to determine a Phase 2 dose, with PDAC as a target indication.
Propanc Biopharma (NASDAQ: PPCB) announced a joint research program to investigate "mesenchymal drift" and how its lead candidate PRP may reverse epithelial-to-mesenchymal transition (EMT) pathways implicated in cancer and fibrosis. Propanc filed a patent application for a PRP-based fibrotic disease treatment and is preparing PRP (trypsinogen + chymotrypsinogen IV) for a Phase 1b first-in-human study in advanced solid tumors scheduled to begin in 2026. The 12-month study will determine maximum tolerated dose and precede multiple Phase 2 proof-of-concept trials.
Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.
The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.
Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and reported Q1 2025/26 results for the quarter ended Sept 30, 2025. Key operational progress includes advancing PRP toward a planned Phase 1b first-in-human study in 30–40 patients in 2026, GMP manufacturing scale-up with purification achieving >95% purity, and Rec-PRP synthetic program moving to formal preclinical development after potency evaluation. IP activity includes multiple patent drafts and a proposed 12‑month extension of the POP1 research program with Universities of Jaén and Granada. Financings: a closed underwritten public offering of 1,000,000 shares at $4.00 ($4.0M gross), Nasdaq trading began Aug 15, 2025, and a $100M private placement facility with an initial $1M tranche received. Quarter-end cash was $600,000 with total current assets of $17M.
Propanc Biopharma (Nasdaq: PPCB) entered a securities purchase agreement with Hexstone Capital for a private placement of up to $100.0 million in Series C convertible preferred stock to support a digital asset acquisition strategy and accelerate R&D. The company received an initial $1.0 million on closing via 100 Series C shares with an initial stated value of $10,000 each.
Propanc issued 9,900 warrants exercisable immediately for one preferred share at $10,000 per share (up to $99.0 million); warrants expire in 12 months. Company expects PRP to enter a First‑In‑Human study in H2 2026. Monthly call feature allows up to 500 warrants to be called per month at $0.01.
Propanc Biopharma (NASDAQ: PPCB) announced a strategic initiative on Nov 4, 2025 to pursue acquisitions of Digital Asset Treasury (DAT) companies trading below Market Cap to Net Asset Value (MNAV). Management said acquiring undervalued DATs could strengthen Propanc's balance sheet, diversify assets, and create long-term shareholder value while the company continues its oncology development work.
The release cites public data showing Bitcoin treasury companies hold approximately $76.9 billion and Ethereum-based DATs hold about $17.6 billion in digital assets. Propanc's board is evaluating targets and building due diligence frameworks and will update shareholders as qualified targets are identified.
FAQ
What is the current stock price of Propanc Bio (PPCB)?
What is the market cap of Propanc Bio (PPCB)?
